Speeding the development of new therapies and diagnostics for glaucoma patients New Horizons Forum Friday, February 9, 2018 Palace Hotel, San Francisco, CA © Aerie Pharmaceuticals, Inc. Irvine, CA 92614 Follow the meeting on Twitter: #Glaucoma360 MLR-0002 Glaucoma Research Foundation thanks the following sponsors WELCOME for their generous support of Glaucoma 360 PLATINUM It is our sincere pleasure to welcome you to the 7th Annual Glaucoma 360: New Horizons Forum, hosted by Glaucoma Research Foundation. This important meeting provides a unique opportunity to bring together leaders in medicine, science, industry, venture capital, and the FDA to discuss emerging ideas in glaucoma and encourage collaboration to accelerate their development for clinical use. Since its establishment in 2012, this annual forum continues to grow and provide the ultimate opportunity to highlight important advances and facilitate networking between these essential groups. As a result, there are now more effective therapies and diagnostic tools in clinical practice today to help doctors manage the disease more effectively. But, unmet medical needs remain in glaucoma. Glaucoma Research Foundation is resolute in its mission to preserve vision and continue its role as a catalyst in the advancement of research towards new treatments and a cure. SILVER Glaucoma 360 would not be possible without the generous and selfless contributions of so many including: members of our Advisory Board, Program and Steering Committees who have volunteered their time to build an outstanding agenda; our dedicated sponsors who have helped to underwrite this event; our speakers, presenters, and panelists who are ready to share their expertise and unique perspectives; our attendees; the support of our Board of Directors and staff at Glaucoma Research Foundation; and the hard working team at The Palace Hotel. Over the past seven years, the field has grown substantially and we are honored and grateful to all of you, for your ongoing dedication to helping patients. Because of your commitment, we now have more options to care for patients than ever before. All proceeds from Glaucoma 360 events will support Glaucoma Research Foundation’s sight-saving endeavors such as the Catalyst for a Cure, a unique collaborative approach to uncover new diagnostic and treatment options for glaucoma. Thank you for your wonderful partnership in our mission. Together, we can truly make a difference in the lives of people living with glaucoma. BRONZE Akorn, Inc. IRIDEX Corporation Optos, Inc. Beaver-Visitec International Lumenis Vision Optovue, Inc. Adrienne L. Graves, PhD Andrew G. Iwach, MD Co-Founder and Co-Chair, Glaucoma 360 Co-Founder and Co-Chair, Glaucoma 360 Ellex Mobius Therapeutics, LLC Quantel Medical Director, Glaucoma Research Foundation Board Chair, Glaucoma Research Foundation Haag-Streit USA Nidek Inc. Shire Icare USA, Inc. Ophthalmic Mutual Insurance Sight Sciences, Inc. Company Wi-Fi sponsored by Santen Inc., Network: Palace Meetings, Password: 2018G360 2018 New Horizons Forum 1 PROGRAM Follow the meeting on Twitter: #Glaucoma360 7:30 – 8:00 am REGISTRATION, BREAKFAST AND EXHIBITS Panelists • Allergan, Inc., Jag Dosanjh, Senior Vice President, Eye Care • Glaukos Corporation, Chris M. Calcaterra, Chief Operating Officer • Heidelberg Engineering, Kfir Azoulay, MBA, Head of Strategy 8:00 – 8:06 am WELCOME AND OPENING REMARKS • Johnson & Johnson Vision, Jane Rady, Vice President, Business Development, Surgical Adrienne L. Graves, PhD and Andrew G. Iwach, MD • New World Medical, Rafael Chan, Chief Commercial Officer Co-Founders and Co-Chairs, Glaucoma 360 • Santen Inc., Ram Palanki, PharmD, Senior Vice President of Commercial, Americas • Carl Zeiss Meditec, Inc., Angelo Rago, Global Head, Ophthalmic Diagnostics 8:06 – 8:32 am OPENING KEYNOTE ADDRESS — Drs. Henry and Frederick Sutro Memorial Lecture Interventional Glaucoma: The Why, The Who, and The How 10:11:26 – 11:31 am INDUSTRY SPOTLIGHT — Allergan, Inc. Speaker Iqbal Ike K. Ahmed, MD, FRCSC Speaker Jag Dosanjh Medical Director, Prism Eye Institute; Associate Professor of Ophthalmology, University of Toronto; Senior Vice President, Eye Care Clinical Professor of Ophthalmology, University of Utah 11:31 – 12:09 pm FUNDING INNOVATIONS: VENTURE CAPITAL PANEL DISCUSSION MORNING CATALYST Moderators Emmett Cunningham, Jr., MD, PhD, MPH Joel S. Schuman, MD, FACS Partner, Clarus Ventures Professor and Chairman of Ophthalmology, NYU Langone Medical Center, NYU School of Medicine; Andrew Gitkin Professor of Electrical and Computer Engineering, NYU Tandon School of Engineering Managing Director and Head of West Coast Biotechnology Banking, Piper Jaffray Panelists • Juliet Bakker, Managing Director and Founder, Longitude Capital • William J. Link, PhD, Founder, Flying L Partners, Managing Director, Versant Ventures 8:34 – 9:09 am NEW HORIZONS IN VIRTUAL REALITY • Heather Preston, MD, Partner and Managing Director, TPG Biotech Moderators Andrew D. Huberman, PhD • Christy Shaffer, PhD, Partner, Hatteras Venture Partners Associate Professor of Neurobiology and Ophthalmology, Stanford University; Member, Catalyst for a Cure Biomarker Initiative Felipe Medeiros, MD, PhD Professor of Ophthalmology, Vice Chair, Technology, Duke University School of Medicine 10:12:09 – 12:14 pm INDUSTRY SPOTLIGHT — Aerie Pharmaceuticals, Inc. Presenting • nGoggle, Inc., Felipe Medeiros, MD, PhD, Professor of Ophthalmology, Vice Chair, Technology, Duke University School of Medicine Speaker Thomas A. Mitro Companies • Vivid Vision, Ben Backus, PhD, Chief Science Officer President and Chief Operating Officer 9:09 – 9:14 am INDUSTRY SPOTLIGHT — Santen Inc. Speaker Ram Palanki, PharmD 12:14 – 1:10 pm NETWORKING BUFFET LUNCHEON Senior Vice President of Commercial, Americas 9:14 – 10:21 am NEW HORIZONS IN GLAUCOMA DEVICES AFTERNOON CATALYST Moderators E. Randy Craven, MD George A. Cioffi, MD Chief, Wilmer Eye Institute – Bethesda; Associate Professor of Ophthalmology, Johns Hopkins University School of Medicine Edward S. Harkness Professor and Chairman, Columbia University College of Physicians and Surgeons; Eydie G. Miller-Ellis, MD Ophthalmologist-in-Chief, New York-Presbyterian Hospital/Columbia University Medical Center Professor of Clinical Ophthalmology, Scheie Eye Institute, University of Pennsylvania Presenting • Alcon, a Novartis Division, Richard A. Lewis, MD, Co-Founder, Sacramento Eye Consultants 1:12 – 2:30 pm NEW HORIZONS IN GLAUCOMA DRUG DELIVERY Companies • Allergan, Inc., Michael Robinson, MD, Vice President and Therapeutic Area Head, Anterior Segment and Consumer Eye Care Moderators James D. Brandt, MD • Camras Vision, Ray Krauss, Chief Executive Officer Director of Glaucoma Service, Professor of Ophthalmology and Visual Science, UC Davis • Ivantis, Inc., Brett A. Trauthen, Chief Scientific Officer Anne L. Coleman, MD, PhD • LumiThera, Clark Tedford, PhD, President and Chief Executive Officer Vice Chair of Department of Ophthalmology, Stein Eye Institute, Frances and Ray Stark Foundation Professor of Ophthalmology, • MicroOptx, Chris Pulling, Chief Executive Officer Stein Eye Institute of the David Geffen School of Medicine, University of California, Los Angeles, Professor of Epidemiology, • Santen Inc., Leonard Pinchuk, PhD, DSc (h.c.), NAE, Founder and Chief Scientific Officer, InnFocus, Inc., a Santen company Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles • Sight Sciences, Inc., Steven Vold, MD, Founder and Chief Executive Officer, Vold Vision; Chief Medical Editor,Glaucoma Today Presenting • Eyenovia, Inc., Shan Lin, MD, Professor of Clinical Ophthalmology, Director, Glaucoma Service, and Director Glaucoma Companies Fellowship Program, Department of Ophthalmology, UCSF • Glaukos Corporation, Jeff Wells, PharmD, Senior Vice President, Clinical, Regulatory and Quality 10:21 – 10:51 am BREAK, EXHIBITS AND NETWORKING OPPORTUNITY • Graybug Vision, Inc., Jeffrey L. Cleland, PhD, President and Chief Executive Officer • Mati Therapeutics, Christopher A. Muller, Chief Commercial Officer • Ocular Therapeutix, Michael H. Goldstein, MD, MBA, Chief Medical Officer • Otero Therapeutics, Morgan V. Fedorchak, PhD, President and Chief Technology Officer; Assistant Professor of Ophthalmology, 10:51 – 11:26 am INDUSTRY PANEL DISCUSSION: GLAUCOMA DEVICES Bioengineering and Clinical & Translational Sciences, University of Pittsburgh Moderators Malik Kahook, MD • Retroject, Inc., Molly Walsh, MD, Founder and Chief Executive Officer Slater Family Endowed Chair of Ophthalmology, Vice Chair, Clinical and Translational Research; • UCSF, Tejal Desai, PhD, Professor and Chair, Department of Bioengineering and Chief, Glaucoma Service and Director, Glaucoma Fellowship, Professor of Ophthalmology, University of Colorado Therapeutic Sciences, School of Pharmacy, UCSF Steven Vold, MD • USC, Mark S. Humayun, MD, PhD, Cornelius J. Pings Chair in Biomedical Sciences, Founder and Chief Executive Officer, Vold Vision; Chief Medical Editor,Glaucoma Today Professor of Ophthalmology, Biomedical Engineering and Integrative Anatomical Sciences, Director of the Institute for Biomedical Therapeutics and Co-Director of the USC Roski Eye Institute 2 Glaucoma Research Foundation 2018 New Horizons Forum 3 PROGRAM (continued) LEADERSHIP 2:30 – 2:35 pm INDUSTRY SPOTLIGHT — Novartis Alcon Pharmaceuticals Speaker Melissa Liew, MD filtering surgery, application of optical coherence tomography in glaucoma, Vice President and US Medical Head of Ophthalmology THOMAS